Welcome to our dedicated page for Establishment Labs Hldgs SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
The Form 4 filing reports a routine equity compensation transaction for Establishment Labs Holdings Inc. (ESTA) director Nicholas Sheridan Lewin. On 30 June 2025, Lewin elected to receive 585 common shares in lieu of his quarterly cash retainer, valued at $42.71 per share under the company’s Outside Director Compensation Policy and issued from the 2018 Equity Incentive Plan. Following the grant, Lewin’s direct ownership increased to 1,075,923 shares, while he also indirectly owns 14,190 shares held by his spouse. No derivative securities were involved, and there were no dispositions. The filing indicates continued board-level alignment with shareholders but does not represent a material change in Lewin’s overall stake or the company’s share structure.